Espinoza Gustavo, Gómez Luz M, Rodríguez-Una Ignacio, Duarte-Bueno Laura M, Parra Juan C, Serrano-Gómez Sergio
Fundación Oftalmológica de Santander.
Universidad Autónoma de Bucaramanga.
J Glaucoma. 2025 Aug 1;34(8):610-615. doi: 10.1097/IJG.0000000000002587. Epub 2025 May 13.
Postoperative pilocarpine use did not significantly alter IOP reduction or medication burden following GATT in patients with OHT and POAG. Furthermore, it had no effect on reducing IOP spikes or the development of PAS.
To evaluate the effect of postoperative pilocarpine use on intraocular pressure (IOP), glaucoma medications, and complications in patients undergoing gonioscopy-assisted transluminal trabeculotomy (GATT).
This retrospective study included patients with ocular hypertension or primary open angle glaucoma who underwent stand-alone GATT or combined with cataract extraction between June 2021 and April 2023. Participants were divided into a pilocarpine group (n=28) and a control group (n=25). Pilocarpine 2% was administered twice daily for 4 weeks following surgery in the pilocarpine group. Outcomes, including IOP, visual acuity, glaucoma medication use, and complications were assessed at multiple postoperative intervals up to 12 months.
Baseline characteristics were similar between groups. Surgical success rates at 12 months were 80.8% for the pilocarpine group and 79.2% for the control group ( P =0.999). No significant differences in IOP reduction were found at any follow-up visit. Considering pilocarpine as 1 drug, the mean number of medications was higher in the pilocarpine group from day 1 to month 1 after surgery ( P <0.001). However, from the third month through the 12-month follow-up, the study groups were comparable. Although postoperative complications were similar, on the first postoperative day, 5 patients (17.9%) in the pilocarpine group exhibited hyphema ≥25%, whereas none in the control group did ( P =0.053).
Routine postoperative pilocarpine use following GATT did not appear to significantly impact surgical outcomes or complication rates. However, given its potential association with greater hyphema extension in the early postoperative period, a rational and selective use, rather than routine administration, might be more appropriate.
对于高眼压症和原发性开角型青光眼患者,术后使用毛果芸香碱对小梁切开辅助房角镜检查术(GATT)后的眼压降低或药物负担没有显著影响。此外,它对降低眼压峰值或周边虹膜前粘连的发生没有作用。
评估术后使用毛果芸香碱对接受小梁切开辅助房角镜检查术(GATT)患者的眼压、青光眼药物治疗及并发症的影响。
这项回顾性研究纳入了2021年6月至2023年4月期间接受单纯GATT或联合白内障摘除术的高眼压症或原发性开角型青光眼患者。参与者被分为毛果芸香碱组(n = 28)和对照组(n = 25)。毛果芸香碱组在术后每天两次给予2%毛果芸香碱,持续4周。在术后长达12个月的多个时间点评估包括眼压、视力、青光眼药物使用及并发症等结果。
两组的基线特征相似。毛果芸香碱组12个月时的手术成功率为80.8%,对照组为79.2%(P = 0.999)。在任何随访中均未发现眼压降低有显著差异。将毛果芸香碱视为1种药物,术后第1天至第1个月,毛果芸香碱组的平均用药数量更高(P < 0.001)。然而,从第3个月至12个月的随访期间,研究组之间具有可比性。尽管术后并发症相似,但在术后第1天,毛果芸香碱组有5例患者(17.9%)出现前房积血≥25%,而对照组无此情况(P = 0.053)。
GATT术后常规使用毛果芸香碱似乎对手术结果或并发症发生率没有显著影响。然而,鉴于其与术后早期前房积血范围扩大的潜在关联,合理且选择性地使用,而非常规给药,可能更为合适。